Animal health company Elanco (NYSE: ELAN) will be reporting results this Wednesday before market hours. Here’s what you need to know.
Elanco beat analysts’ revenue expectations last quarter, reporting revenues of $1.37 billion, up 14.9% year on year. It was a satisfactory quarter for the company, with a beat of analysts’ EPS estimates but EBITDA guidance for next quarter missing analysts’ expectations.
Is Elanco a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Elanco’s revenue to grow 5.8% year on year, in line with the 4.8% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Elanco rarely misses Wall Street’s revenue estimates.
Looking at Elanco’s peers in the pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Ocular Therapeutix posted flat year-on-year revenue, beating analysts’ expectations by 5.3%, and Jazz Pharmaceuticals reported revenues up 15.5%, topping estimates by 8.3%.
Read our full analysis of Ocular Therapeutix’s results here and Jazz Pharmaceuticals’s results here.
Investors in the pharmaceuticals segment have had steady hands going into earnings, with share prices up 1.9% on average over the last month. Elanco is up 2.3% during the same time and is heading into earnings with an average analyst price target of $30.07 (compared to the current share price of $25.71).
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
